Hybryte™ expanded efficacy and safety data presented at the american academy of dermatology meeting

Princeton, n.j., april 26, 2021 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that ellen kim, md, medical director, dermatology clinic, perelman center for advanced medicine, professor of dermatology at the hospital of the university of pennsylvania, and the lead principal investigator for the phase 3 flash (fluorescent light activated synthetic hypericin) study, delivered a presentation at the american academy of dermatology (aad) association virtual meeting experience, held april 23-25, 2021.
SNGX Ratings Summary
SNGX Quant Ranking